Drug Trial Radar · NCT04486378
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
327
Planned (sponsor's estimate)
Start
Mar 8, 2021
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Genentech, Inc.
- First posted
- Jul 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Conditions
- Colorectal Cancer Stage II
- Colorectal Cancer Stage III
Interventions
RO7198457 intravenous (IV)Drug
RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
Observational group (no intervention)Other
watchful waiting
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survival (DFS)Time frame: Through study completion, up to 5 years
Locations
85 sites in 7 countries. Site status is shown where the registry gives one.
Marin Cancer Care
Greenbrae, California
Indiana University Melvin and Bren Simon Comprehensive Cancer
Indianapolis, Indiana
Allina Health
Minneapolis, Minnesota
Oncology Hematology Care Clinical Trials
Cincinnati, Ohio
Rhode Island Hospital
Providence, Rhode Island
Sarah Cannon (Tennessee Oncology - Nashville)
Nashville, Tennessee
Texas Oncology, P.A. - Austin
Austin, Texas
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Texas Oncology-San Antonio Medical Center
San Antonio, Texas
Texas Oncology - Northeast Texas
Tyler, Texas
Virginia Cancer Specialists
Fairfax, Virginia
University of Washington
Seattle, Washington
Northwest Cancer Specialists P.C.
Vancouver, Washington
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Imeldaziekenhuis General Hospital
Bonheiden, Belgium
VZW Algemeen Ziekenhuis AZ Klina
Brasschaat, Belgium
GHDC (Grand Hopital de Charleroi)
Charleroi, Belgium
AZ Groeninge
Kortrijk, Belgium
Centres Hospitaliers Jolimont
La Louvière, Belgium
Universitaire Ziekenhuizen Leuven
Leuven, Belgium
AZ Delta Roeselare
Roeselare, Belgium
GasthuisZusters Antwerpen - Sint-Augustinus
Wilrijk, Belgium
The Ottawa Hospital Cancer Centre
Ottawa, Canada
Princess Margaret Cancer Centre
Toronto, Canada
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitaetsklinikum St. Josef-Hospital Bochum
Bochum, Germany
Universitätsklinikum Bonn, Med. Klinik u. Poliklinik I
Bonn, Germany
Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF)
Frankfurt am Main, Germany
Studiengesellschaft BSF
Halle, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Hämatologisch-Onkologische Praxis Eppendorf
Hamburg, Germany
Asklepios Klinik Altona
Hamburg, Germany
Medizinische Hochschule Hannover
Hanover, Germany
National Center for Tumor Diseases (NCT) Heidelberg
Heidelberg, Germany
SLK-Kliniken Heilbronn GmbH
Heilbronn, Germany
Universitaetsklinikum Leipzig AoeR
Leipzig, Germany
Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR
Mainz, Germany
LMU Klinikum (Campus Großhadern) Medizinische Klinik Universität München
München, Germany
OhO Ostholstein Onkologie
Oldenburg in Holstein, Germany
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.